This Article  • Full text  • PDF  • Author in the Room Audio  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (48)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Tuberculosis/ Other Mycobacterium  • World Health  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Henry M. Blumberg, MD; Michael K. Leonard, Jr, MD; Robert M. Jasmer, MD

JAMA. 2005;293:2776-2784.

Tuberculosis (TB) has emerged as a global public health epidemic. Despite decreasing numbers of cases in the United States since 1992, TB remains a serious public health problem among certain patient populations and is highly prevalent in many urban areas. The responsibility for prescribing an appropriate drug regimen and ensuring that treatment is completed is assigned to the public health program or the clinician not to the patient. The initial prescribed regimen for the treatment of TB usually consists of 4 drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. The minimum length for the treatment of drug-susceptible TB with a rifampin-based regimen is 6 to 9 months. Providing medications directly to the patient and watching him/her swallow the anti-TB drugs, which is termed directly observed therapy, is recommended for all patients diagnosed with TB and can help ensure higher completion rates, prevent the emergence of drug resistant TB, and enhance TB control. There has been renewed interest in the treatment of those with latent TB infection as a TB-control strategy in the United States for eliminating the large reservoir of individuals at risk for progression to TB. The 2 broad categories of persons who should be tested for latent TB infection are those who are likely to have been recently infected (such as contacts to infectious TB cases) and persons who are at increased risk of progression to TB disease following infection with Mycobacterium tuberculosis (eg, human immunodeficiency virus infection and selected medical conditions; recent immigrants to the United States from high TB-burden countries). The preferred regimen for the treatment of latent TB infection is 9 months of isoniazid. There is now renewed interest in and great need for the development of new drugs to treat TB and latent TB infection.

Author Affiliations: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Ga (Drs Blumberg and Leonard); Epidemiology Department, Grady Memorial Hospital, Atlanta, Ga (Dr Blumberg); and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco (Dr Jasmer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Needed: New and Better Tools to Combat Latent Tuberculosis Infection
Blumberg
ANN INTERN MED 2008;149:761-763.
FULL TEXT  

Scrotal Tuberculosis in Adult Patients: A 10-Year Clinical Experience
Lee et al.
Am J Trop Med Hyg 2007;77:714-718.
ABSTRACT | FULL TEXT  

Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth
Long et al.
J Antimicrob Chemother 2007;59:118-121.
ABSTRACT | FULL TEXT  

The Fight Against Tuberculosis
Scheindlin
Mol. Interv. 2006;6:124-130.
FULL TEXT  

21-Year-Old Woman With Flank Pain
Siddiqui and Thompson
Mayo Clin Proc. 2006;81:673-676.
FULL TEXT  

Challenges of tuberculosis control
Murray
CMAJ 2006;174:33-34.
FULL TEXT  

Tuberculosis--A Global Problem Requiring a Global Solution
DeAngelis and Flanagin
JAMA 2005;293:2793-2794.
FULL TEXT